AR048970A1 - Formulacion farmaceutica solida - Google Patents

Formulacion farmaceutica solida

Info

Publication number
AR048970A1
AR048970A1 ARP050102057A ARP050102057A AR048970A1 AR 048970 A1 AR048970 A1 AR 048970A1 AR P050102057 A ARP050102057 A AR P050102057A AR P050102057 A ARP050102057 A AR P050102057A AR 048970 A1 AR048970 A1 AR 048970A1
Authority
AR
Argentina
Prior art keywords
solid pharmaceutical
pharmaceutical formulation
pregelatinized starch
starch
formulation
Prior art date
Application number
ARP050102057A
Other languages
English (en)
Inventor
Tadashi Mukal
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35428258&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR048970(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR048970A1 publication Critical patent/AR048970A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una formulacion farmacéutica solida que posee elevada resistencia física y propiedades de liberacion de droga excelentes y además posee digestibilidad de excipientes cuando es administrada, la cual comprende (a) un ingrediente medicinal activo (como por ejemplo cilostazol), y (b) un almidon pregelatinizado en una cantidad de 10 a 90% en peso, siendo dicho almidon pregelatinizado preparado por pregelatinizacion de un almidon economico usual y estable durante el procedimiento de la formulacion. También se provee un método para preparar la formulacion farmacéutica solida.
ARP050102057A 2004-05-20 2005-05-19 Formulacion farmaceutica solida AR048970A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004150557 2004-05-20

Publications (1)

Publication Number Publication Date
AR048970A1 true AR048970A1 (es) 2006-06-14

Family

ID=35428258

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102057A AR048970A1 (es) 2004-05-20 2005-05-19 Formulacion farmaceutica solida

Country Status (15)

Country Link
US (1) US8821936B2 (es)
EP (1) EP1755682A4 (es)
KR (2) KR20120030606A (es)
CN (1) CN1984682B (es)
AR (1) AR048970A1 (es)
AU (1) AU2005244707B2 (es)
BR (1) BRPI0511298A (es)
CA (1) CA2567400C (es)
HK (1) HK1105358A1 (es)
MX (1) MXPA06013407A (es)
MY (1) MY153696A (es)
RU (1) RU2390332C2 (es)
SG (1) SG152285A1 (es)
TW (1) TWI338583B (es)
WO (1) WO2005113009A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101516403B (zh) * 2006-09-14 2013-10-02 安斯泰来制药株式会社 口腔崩解片及其制备方法
GB0618879D0 (en) * 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
AR071706A1 (es) * 2008-05-15 2010-07-07 Otsuka Pharma Co Ltd Una formulacion farmaceutica de cilostazol solida de liberacion sostenida y metodo de preparacion.
EP3409294A1 (en) 2017-06-01 2018-12-05 Przedsiebiorstwo Farmaceutyczne Lek-Am Sp Z O. O. Tablets containing cilostazol of specific particle size distribution
RU2686066C1 (ru) * 2018-05-11 2019-04-24 Общество С Ограниченной Ответственностью "Валента-Интеллект" Лекарственная форма цилостазола замедленного высвобождения

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB825892A (en) * 1957-05-24 1959-12-23 Ici Ltd Tabletting process
US4266348A (en) * 1978-12-15 1981-05-12 Cpc International Inc. Fluidized bed process
GB8624213D0 (en) 1986-10-09 1986-11-12 Sandoz Canada Inc Sustained release pharmaceutical compositions
US4755397A (en) 1986-12-24 1988-07-05 National Starch And Chemical Corporation Starch based particulate encapsulation process
FR2610827B1 (fr) 1987-02-18 1991-09-13 Pf Medicament Comprime de dihydroergotamine (d.h.e.) du type a matrice hydrophile et son procede de fabrication
FR2618073B1 (fr) 1987-07-16 1990-09-07 Pf Medicament Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation
US5073380A (en) 1987-07-27 1991-12-17 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
FR2666506A1 (fr) 1990-09-07 1992-03-13 Pf Medicament Comprime a liberation prolongee a base de 5-mononitrate d'isosorbide et son procede de preparation.
CN1168102A (zh) 1995-01-10 1997-12-17 大制药株式会社 树脂微粒及含该树脂微粒的药用材料和药剂
JP4022269B2 (ja) * 1995-05-26 2007-12-12 協和醗酵工業株式会社 医薬組成物
WO1997004752A1 (en) 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
ATE206304T1 (de) * 1995-12-27 2001-10-15 Janssen Pharmaceutica Nv Bioadhesive feste arzneimittelform
US6287596B1 (en) * 1996-07-12 2001-09-11 Daiichi Pharmaceutical Co., Ltd. Quickly disintegratable compression-molded materials and process for producing the same
WO1998018610A1 (en) 1996-10-28 1998-05-07 Lengerich Bernhard H Van Embedding and encapsulation of controlled release particles
JPH10182701A (ja) * 1996-12-26 1998-07-07 Sanei Toka Kk 溶出性向上粉末及びその製造方法
US6129932A (en) * 1997-09-05 2000-10-10 Merck & Co., Inc. Compositions for inhibiting platelet aggregation
JPH11286456A (ja) 1998-03-31 1999-10-19 Lion Corp 複合粉体組成物及び錠剤
WO1999056666A1 (en) 1998-05-01 1999-11-11 Rt Alamo Ventures, Inc. The treatment of sexual dysfunction in certain patient groups
WO2000054752A1 (fr) * 1999-03-15 2000-09-21 Kaken Pharmaceutical Co., Ltd. Comprimes a delitement rapide et procede de fabrication
JP4748839B2 (ja) 1999-03-25 2011-08-17 大塚製薬株式会社 シロスタゾール製剤
EG23951A (en) 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
US6667060B1 (en) 1999-03-31 2003-12-23 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
FR2798289B1 (fr) * 1999-09-15 2004-12-31 Cll Pharma Formes galeniques a delitement rapide en bouche et leur procede de preparation
US7138143B1 (en) 1999-09-30 2006-11-21 Otsuka Pharmaceutical Company, Limited Coated preparation soluble in the lower digestive tract
IL151838A0 (en) 2000-03-20 2003-04-10 Teva Pharma Processes for preparing 6-hydroxy-3,4-dihydroquinolinone, cilostazol and n- (4-methoxyphenyl)-3-chloropropionamide
US6515128B2 (en) 2000-03-20 2003-02-04 Teva Pharmaceutical Industries Ltd. Processes for preparing cilostazol
JP4637338B2 (ja) 2000-09-22 2011-02-23 大塚製薬株式会社 シロスタゾール有核錠
JP2002193792A (ja) * 2000-12-25 2002-07-10 Lion Corp フィルムコーティング錠剤及びエロージョン防止組成物
JP2003063965A (ja) 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
US6509040B1 (en) * 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
US6388080B1 (en) 2001-06-29 2002-05-14 Grayson Walker Stowell Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
US6531603B1 (en) 2001-06-29 2003-03-11 Grayson Walker Stowell Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
US6596871B2 (en) 2001-06-29 2003-07-22 Grayson Walker Stowell Polymorphic forms of 6-[4-(1-cyclohexyl-1h-tetraol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
CN1210026C (zh) * 2002-10-09 2005-07-13 重庆太极医药研究院 褪黑素双层控释片及制备工艺
MXPA05004422A (es) * 2002-10-25 2007-11-22 Collegium Pharmaceutical Inc Composiciones de milnacipran de liberacion pulsatil.
US20050255155A1 (en) * 2004-05-11 2005-11-17 Glenmark Pharmaceuticals Limited Modified release cilostazol compositions

Also Published As

Publication number Publication date
RU2006145311A (ru) 2008-07-10
RU2390332C2 (ru) 2010-05-27
KR101302810B1 (ko) 2013-09-02
KR20070034002A (ko) 2007-03-27
TW200538161A (en) 2005-12-01
TWI338583B (en) 2011-03-11
SG152285A1 (en) 2009-05-29
AU2005244707B2 (en) 2011-08-11
US20080033009A1 (en) 2008-02-07
CN1984682A (zh) 2007-06-20
CA2567400C (en) 2012-09-25
WO2005113009A1 (en) 2005-12-01
AU2005244707A1 (en) 2005-12-01
US8821936B2 (en) 2014-09-02
HK1105358A1 (en) 2008-02-15
KR20120030606A (ko) 2012-03-28
CA2567400A1 (en) 2005-12-01
CN1984682B (zh) 2012-06-06
MXPA06013407A (es) 2007-01-23
MY153696A (en) 2015-03-13
EP1755682A1 (en) 2007-02-28
EP1755682A4 (en) 2012-11-07
BRPI0511298A (pt) 2007-12-04

Similar Documents

Publication Publication Date Title
ECSP18089087A (es) Formulación para compresión directa y proceso
AR047993A1 (es) Composicion farmaceutica que comprende pimobendano
AR110986A2 (es) Composiciones de ecteinascidina, formulaciones liofilizadas, método de preparación y uso
BR122019027412B8 (pt) composição farmacêutica de liberação sustentada na forma de micropartículas, processo para preparação das ditas micropartículas, e kit de administração
AR054382A1 (es) Formulacion de compresion directa de un inhibidor de dipeptidil-peptidasa iv y una glitazona y proceso
ECSP077987A (es) Formulación de 1-[(3-hidroxi-adamant-1-ilamino)-acetil]-pirrolidin-2(s)-carbonitrilo de liberación modificada
BRPI0922796A2 (pt) Comprimido farmacêutico para administração por via oral e método de fabricação do mesmo
ECSP088239A (es) Composición de liberación de fármaco sostenida
CL2016001411A1 (es) Unidad de dosificación farmacéutica solida de desintegración oral que comprende un componente de estetrol; metodo de preparación; uso para la anticoncepción femenina y en terápia de sustitución hormonal femenina.
MX2010003923A (es) Formulacion farmaceutica de valsartan.
NZ593045A (en) Pharmaceutical dosage form comprising nifedipine or nisoldipine and an angiotensin-ii antagonist and/or a diuretic
AR057946A1 (es) Formulacion de zonisamida de liberacion sostenidda
UA105766C2 (uk) Фармацевтична композиція, яка містить сіль стронцію, вітамін d і циклодекстрин
MY143549A (en) Compositions for external application, containing adenosyl cobalamin for improvement of skin diseases
CY1111442T1 (el) Ενωσεις πιπεριδινης και χρησεις αυτων
PE20061314A1 (es) Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo
AR061790A1 (es) Composicion farmaceutica solida para la administracion oral, formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina, y su uso en la manufactura de un medicamento
ECSP034826A (es) Método para fabricar una composición farmacéutica de dosis baja
AR048970A1 (es) Formulacion farmaceutica solida
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
CO6640318A2 (es) Formas de dosificación oral de bendamustina
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
PE20091900A1 (es) Una formulacion farmaceutica solida
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.

Legal Events

Date Code Title Description
FB Suspension of granting procedure